Literature DB >> 24611095

Identification of patients with defects in the globin genes.

Domenico Dell'edera1, Annunziata Anna Epifania2, Giusi Natalia Milazzo3, Manuela Leo1, Carmela Santacesaria1, Arianna Allegretti1, Eleonora Mazzone1, Paolo Panetta4, Giovanna Iammarino5, Maria Giovanna Lupo1, Rocchina Barbieri6, Maria Brigida Lioi6.   

Abstract

INTRODUCTION: hemoglobinopathies constitute a major health problem worldwide. These disorders are characterized by a clinical and hematological phenotypic heterogeneity. The increase of HbA2 is an invaluable hematological marker of the beta-thalassemia heterozygosis and of double heterozygosis for the alleles of delta and alpha globin genes or for the alleles of delta and beta globin genes which can cause the increase of HbA2 up to normal or borderline values. CASE REPORT: we report the case of a 30-year-old woman (first pregnant) who was admitted to our Unit at 12 weeks for a screening for thalassemia. The outcomes of the biochemical and haematological exams (MCV, MCH, HbA2, HbF) highlighted that the patient was a carrier of a beta-thalassemic trait. Molecular analysis of the beta globin genes highlighted a β(0)39C>T heterozygous mutation. Biochemical and hematological parameters of the husband (MCV, MCH, HbA2, HbF) were normal except for the level of HbA2 (3,6%). The molecular analysis of the beta globin genes highlighted a IVS2 nt844 C>G heterozygous mutation. Furthermore, the heterozygous mutation δ(+)cod.27G>T was detected in his δ globin gene. For this reason, he was diagnosed a δ+β Thal.
CONCLUSIONS: the aim of this paper is to highlight that biochemical diagnosis could not exhaustive and a molecular diagnostic widening is required to detect the genetic deficiency causing the thalassemic trait.

Entities:  

Keywords:  HbA2 borderline; carrier screening; prenatal diagnosis; β-thalassemia

Year:  2013        PMID: 24611095      PMCID: PMC3931278     

Source DB:  PubMed          Journal:  J Prenat Med        ISSN: 1971-3282


  8 in total

1.  Molecular diagnosis of hemoglobinopathies and thalassemia.

Authors:  Yuet Wai Kan; Judy C Chang
Journal:  Prenat Diagn       Date:  2010-07       Impact factor: 3.050

Review 2.  The role of haemoglobin A(2) testing in the diagnosis of thalassaemias and related haemoglobinopathies.

Authors:  A Mosca; R Paleari; G Ivaldi; R Galanello; P C Giordano
Journal:  J Clin Pathol       Date:  2009-01       Impact factor: 3.411

3.  Determination of Hb F levels: the routine methods.

Authors:  C Préhu; R Ducrocq; C Godart; J Riou; F Galactéros
Journal:  Hemoglobin       Date:  1998 Sep-Nov       Impact factor: 0.849

Review 4.  Gamma chain abnormal human fetal hemoglobin variants.

Authors:  T H Huisman
Journal:  Am J Hematol       Date:  1997-07       Impact factor: 10.047

Review 5.  Genetic modifiers of beta-thalassemia.

Authors:  Swee Lay Thein
Journal:  Haematologica       Date:  2005-05       Impact factor: 9.941

6.  [Importance of the molecular diagnosis in the screening of alpha-thalassemia].

Authors:  Domenico Dell'Edera; Antonio Malvasi; Andrea Tinelli; Eleonora Mazzone; Manuela Leo; Vito Monti; Annunziata Anna Epifania
Journal:  Recenti Prog Med       Date:  2011 Jul-Aug

7.  Incidence of β-thalassemia carrier on 1495 couples in preconceptional period.

Authors:  Domenico Dell'Edera; Annunziata Anna Epifania; Antonio Malvasi; Elena Pacella; Andrea Tinelli; Antonio Capalbo; Maria Brigida Lioi; Giancarlo Di Renzo
Journal:  J Matern Fetal Neonatal Med       Date:  2012-10-30

Review 8.  The relevance of hemoglobin F measurement in the diagnosis of thalassemias and related hemoglobinopathies.

Authors:  Andrea Mosca; Renata Paleari; Daniela Leone; Giovanni Ivaldi
Journal:  Clin Biochem       Date:  2009-07-04       Impact factor: 3.281

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.